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Aim To test the association of NOS3 gene with hypoxic-
ischemic encephalopathy (HIE).
Methods The study included 110 unrelated term or pre-
term born children (69 boys and 41 girls) with HIE and 
128 term and preterm born children (60 boys and 68 girls) 
without any neurological problems after the second year 
of life. Children with perinatal HIE fulfilled the diagnos-
tic criteria for perinatal asphyxia. All children were admit-
ted to the Clinical Hospital Split between 1992 and 2008. 
We analyzed 6 tagging single nucleotide polymorphisms 
(SNP) within NOS3 gene (rs3918186, rs3918188, rs1800783, 
rs1808593, rs3918227, rs1799983), in addition to previously 
confirmed  NOS3-associated  SNP  rs1800779.  Genotyping 
was conducted using real-time polymerase chain reaction 
(PCR). Association analyses were performed according to 
allelic and genotypic distribution.
Results  Allelic  test  did  not  show  any  SNP  association 
with  HIE.  SNP  rs1808593  showed  genotype  association 
(P = 0.008) and rs1800783-rs1800779 TG haplotype showed 
an association with HIE (P < 0.001). The study had 80% sta-
tistical power to detect (α = 0.05) an effect with odds ra-
tio  (OR) = 2.07  for  rs3918186,  OR = 1.69  for  rs3918188, 
OR = 1.70 for rs1800783, OR = 1.80 for rs1808593, OR = 2.10 
for rs3918227, OR = 1.68 for rs1800779, and OR = 1.76 for 
rs1799983, assuming an additive model.
Conclusion Despite the limited number of HIE patients, 
we  observed  genotypic  and  haplotype  associations  of 
NOS3 polymorphisms with HIE.
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Hypoxic-ischemic  encephalopathy  (HIE)  in  the  perinatal 
period is a very serious neurological problem in children. It 
causes long-term or permanent damage, such as cerebral 
palsy, epilepsy, certain forms of mental retardation, and 
cognitive and sensory disorders in a relatively large num-
ber of affected children (1,2). HIE occurs in premature and 
full-term children after intrauterine infection and/or cho-
rioamnionitis, premature rupture of membranes, maternal 
trauma, shock, or other etiologies. Premature infants are a 
particularly vulnerable group for the occurrence of hem-
orrhagic and hypoxic-ischemic brain damage, and the in-
cidence of these injuries is higher in children with lower 
gestational ages (1,3). All of these conditions impair cere-
bral blood flow, leading to ischemia and hypoxia and start 
a cascade of deleterious biochemical events that seriously 
and permanently injure the brain (2).
The main events during ischemia are an accumulation of 
free radicals, creation of excitatory neurotransmitters in se-
lectively vulnerable areas, lack of adenosine triphosphate, 
and increase in intracellular calcium. Free radicals are high-
ly reactive and cause damage of lipids, DNA, and proteins, 
which leads to neuronal death. One of the important radi-
cals in this event is nitric oxide (2,4). Nitric oxide is a weak 
free radical formed during the conversion of l-arginine to 
L-citrulline by nitric oxide synthase (NOS). There are two 
isoforms of NOS: constitutive and inducible (NOS2). Con-
stitutive NOS is active in vascular endothelial cells and is 
called endothelial nitric oxide synthase (NOS3), while the 
NOS which is active in the central and peripheral nervous 
system is called neuronal nitric oxide synthase (NOS1) (5).
The role of nitric oxide in the pathogenesis of ischemic 
brain damage is dual: protective and deleterious, depend-
ing on NOS isoform and the type of the cell that produc-
es nitric oxide. It also depends on the term and intensity 
of oxidative stress (4). In an intense oxidative stress, nitric 
oxide produced by NOS1 leads to neuronal death, caus-
ing mitochondrial damage, loss of energy, and further dis-
ruption of calcium homeostasis (4). Nitric oxide produced 
by NOS3 has a protective role. Mild exposure to ischemia 
activates enzyme NOS3 and produces small amounts of 
nitric oxide with subsequent relaxation of blood vessels 
and vasodilatation. The nitric oxide produced by NOS3 
plays a prominent role in maintaining cerebral blood flow 
and preventing neuronal injury (6). It has several different 
roles, such as inhibition of platelet aggregation, inhibition 
of platelet and leukocyte adhesion to endothelium, relax-
ation and inhibition of smooth blood vessel muscle cells 
proliferation, stimulation of angiogenesis, anti-inflamma-
tory action, and prevention of oxidative damage (6). Be-
cause of the very important role of nitric oxide in these 
processes, impaired nitric oxide synthesis by NOS3 in vas-
cular endothelial cells, may contribute to ischemic dam-
age (7). Understanding this dual role of NOS and nitric ox-
ide in the brain ischemia may lead us to prevention and 
treatment of ischemic damage (8).
Nitric oxide production in blood vessels is controlled by 
NOS3 gene located on the chromosome 7q36.1, which 
contains 26 coding exons and has genomic size of 21kb 
(6). It has been reported that NOS3 gene polymorphisms 
may lead to reduction or disruption of gene transcription, 
altering enzymatic function, and therefore cause suscep-
tibility to ischemic brain diseases (9). So far, several gene 
polymorphisms of NOS3 have been found to be associat-
ed with cerebrovascular disease: Glu298Asp, also known 
as E298D, or G894T (rs1799983) in exon 7; a variable num-
ber of 27 bp nucleotide tandem repeat sequences (VNTR, 
27pb) in intron 4; and T786C polymorphism (rs2070744) in 
the 5’ region of NOS3 (10). Another NOS3 gene polymor-
phism, -922A/G (rs1800779), showed an association with 
ischemic stroke (11). However, the results are still ambigu-
ous, and functional consequences of NOS3 polymorphisms 
have not yet been completely clarified. There seems to be a 
correlation of NOS3 polymorphisms with the clinical mani-
festation of perinatal and neonatal diseases (12). Our study 
aims to clarify the role and impact of 7 NOS3 gene poly-
morphisms on the occurrence of perinatal HIE.
MaTERiaL anD METhoDS
Participants
The  study  included  110  unrelated  full-term  or  preterm 
born children (69 boys and 41 girls) with hypoxic-ischemic 
injury and intracranial hemorrhage (HIE group). The con-
trol group consisted of 128 apparently healthy full-term 
and preterm born children (60 boys and 68 girls), without 
any neurological problems after the second year of life 
(control group), who were admitted to the Clinical Hospi-
tal Split between 1992 and 2008. All children with perina-
tal hypoxic-ischemic injury fulfilled the diagnostic criteria 
for perinatal asphyxia: fetal heart frequency during delivery 
<100 or >160 per min, and/or Apgar score at 5-minute ≤7, 
and/or blood gases pH≤7.1. The clinical course of HIE was 
mild, moderate, or severe for all the affected children ac-
cording to the classification (13). The HIE was confirmed 
with brain ultrasound. Routine cranial sonography was 
performed on preterm infants (gestational age less MOLECULAR MEDICINE 398 Croat Med J. 2011; 52: 396-402
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than 37 weeks) on the first day of life and was repeated at 
least once during the first week and at the 2nd and at 4th-
6th week of age. The cranial sonography was performed 
on infants born at 37 weeks gestational age or later de-
pending  on  clinical  indications.  Hypoxic-ischemic  injury 
and intracranial hemorrhage were confirmed by magnetic 
resonance imaging at the age of 2 years. The HIE group 
consisted of 72.7% of patients with hypoxic-ischemic in-
jury and of 27.3% of patients with hypoxic-ischemic inju-
ry accompanied with intracranial hemorrhages. The study 
was approved by the Ethics Committee of Clinical Hospi-
tal Center Split and School of Medicine Split, and informed 
consent was obtained from patients’ parents prior to the 
blood sampling.
Dna extraction and genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes  using  the  Perfect  gDNA  kit  (Eppendorf,  Ham-
burg, Germany). Six haplotype-tagging SNPs (rs3918186, 
rs3918188,  rs1800783,  rs1808593,  rs3918227,  rs1799983) 
were selected across the NOS3 gene using the Tagger soft-
ware (http://www.broad.mit.edu/mpg/tagger/server.html) 
(14). The proportion of variation across the NOS3 gene re-
gion captured by tagSNPs was calculated based on the 
HapMap phase II using the same software (15). The SNP 
rs1800779 was also analyzed in this study because of its 
more common association with the development of HIE 
(16,17). Real-time polymerase chain reaction (PCR) anal-
ysis for 7 NOS3 polymorphisms was performed using an 
ABIPRISM 7500 Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA) and pre-developed TaqMan 
assay reagents. PCR was carried out according to the man-
ufacturer’s protocol.
Statistical analysis
Prior to association analysis, we performed quality control 
of the obtained genotypes. We tested genotyping rate, 
Hardy-Weinberg equilibrium (HWE), and minor allele fre-
quencies (MAF) for all samples using HaploView 4.1. MAFs 
were compared with the National Center for Biotechnol-
ogy Information SNP database (NCBI dbSNP), MAFs for the 
Central European population (www.ncbi.nlm.nih.gov/proj-
ects/SNP/). Case-control single-point and multi-point as-
sociation analyses were carried out using Haploview 4.1. 
Haplotype frequencies were estimated using the expecta-
tion-maximization algorithm implemented in HaploView 
4.1. P-value lower than 0.05 was considered significant. 
Calculations of 80% power study at α = 0.05 were 
performed using Quanto. The results are expressed as OR. 
When OR>1, genotype confers sensitivity to the effects of 
exposure (18).
RESuLTS
The control group of 128 participants consisted of 38.2% 
of full-term infants (≥37 gestation weeks), 26.6% of pre-
term infants of 32-36 gestation weeks, and 35.2% of pre-
term infants of <32 gestation weeks, while HIE group of 
110 infants consisted of 18.2% of full-term infants, 34.5% 
of preterm infants of 32-36 gestation weeks, and 47.3% 
of preterm infants of <32 gestation weeks. Genotype call 
rate was 100% for all the investigated SNPs. Genotypes in 
cases and controls fit HWE, except for rs1808593, which 
slightly deviated from HWE in controls (P = 0.0023). MAFs 
in controls were concordant with NCBI dbSNP frequencies 
for the Central European population. The 6 analyzed NOS3 
tagSNPs  –  rs3918186,  rs3918188,  rs1800783,  rs1808593, 
rs3918227, rs1799983 – captured 100% of NOS3 common 
variation at the r2 = 0.8, based on the HapMap phase II data. 
Linkage disequilibrium pattern of analyzed SNPs is shown 
in Figure 1. Allelic test did not find any SNP association with 
HIE (Table 1). However, genotypic test detected an associa-
tion of rs1808593 tagSNP with HIE (χ2 = 9.625, P = 0.0081). In 
the group of patients with HIE, TG genotype was found less 
Figure 1.
Linkage disequilibrium r2 values of 7 NOS3 single nucleotide polymor-
phisms in the affected group of children with hypoxic-ischemic enceph-
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frequently and GG genotype more frequently than in con-
trols (Table 2). We also observed rs1800783-rs1800779 TG 
haplotype association with HIE (χ2 = 11.769, P < 0.001) (Ta-
ble 3). Genotypic and allelic distribution did not correlate 
with gestation age in either HIE or control group.
Our study had 80% statistical power to detect (α = 0.05) an 
effect with odds ratio (OR) = 2.07 for rs3918186, OR = 1.69 
for  rs3918188,  OR = 1.70  for  rs1800783,  OR = 1.80  for 
rs1808593, OR = 2.10 for rs3918227, OR = 1.68 for rs1800779, 
and OR = 1.76 for rs1799983, assuming an additive model.
DiScuSSion
Our study did not demonstrate the association of any SNP 
with HIE. SNP rs1808593 showed genotype association and 
rs1800783-rs1800779 TG haplotype showed an association 
with HIE. Several recently published articles applied similar 
approach to the analysis of tagging polymorphisms but in 
correlation with other vascular disorders (19,20).
Nitric oxide produced in blood vessels is a well-known 
and important vasodilatator with a pivotal role in main-
taining vascular tone in both the cerebral and systemic 
circulation  (4,11).  Hypoxia-ischemia  increases  the  influx 
of calcium in endothelial cells of blood vessels and acti-
vates NOS3, which leads to generation of nitric oxide, re-
laxation of smooth muscle cells, regulation of the blood 
flow through the tissue, and reduction of harmful effects 
of hypoxia and ischemia (4). A number of studies have in-
vestigated the association of polymorphisms in NOS3 gene 
with the occurrence of cerebral palsy, however only two 
studies have confirmed it (21,22). It seems that the poly-
morphism rs1799983 (-894G>T) located in the promotor 
region and the 5 tandem repeats in a 27-bp sequence in 
intron 4 of NOS3, 4a4b, are associated with variable plasma 
levels of nitric oxide (23,24). Also the rare C allele of the 
-786T>C (rs2070744) polymorphism in the 5’-flanking re-
gion of the gene has been shown to significantly reduce 
the activity of NOS3 promoter (25). We observed the asso-
ciations of rs1800783 (-1474 T/A) - rs1800779 (-922 G>A) 
haplotype and perinatal HIE. The frequency of the rare 
rs1800783-rs1800779 TG haplotype in our study was 2% 
in cases and 4% in controls, suggesting that it might 
have a protective role against HIE. However, since it 
TaBLE 1. case-control results of 7 investigated NOS3 single 
nucleotide polymorphism (SnP) in hypoxic-ischemic enceph-
alopathy group of 110 affected children and 128 controls
SnP
Minor 
allele MaF*-cases MaF-controls χ2 P
rs1800783 A 0.368 0.406 0.722 0.3956
rs1800779 G 0.405 0.398 0.018 0.8922
rs1799983 T 0.290 0.300 0.055 0.8141
rs3918227 A 0.081 0.082 0.0 0.9933
rs3918186 T 0.113 0.117 0.015 0.9038
rs3918188 A 0.377 0.340 0.722 0.3955
rs1808593 G 0.227 0.281 1.809 0.1787
*MaF – minor allele frequencies.
TaBLE 2. Genotype analysis of 7 investigated NOS3 single 
nucleotide polymorphisms (SnP) with hypoxic-ischemic 
encephalopathy (hiE)
no. (%) of participants in
SnP genotype hiE group control group χ2 P
rs1800783
TT 43 (39.1)   43 (33.6) 0.821 0.6633
TA 53 (48.2)   66 (51.6)
AA 14 (12.7)   19 (14.8)
rs1800779
GG 17 (15.5)   18 (14.0) 0.063 0.968
GA 55 (50.0)   66 (51.6)
AA 38 (34.5)   44 (34.4)
rs1799983
GG 52 (47.3)   60 (46.9) 0.28 0.869
GT 52 (47.3)   59 (46.1)
TT   6 (5.4)     9 (7.0)
rs3918227
CC 93 (84.5) 108 (84.4) 0.0159 0.9924
CA 16 (14.5)   19 (14.8)
AA   1 (1.0)     1 (0.8)
rs3918186
AA 87 (79.1) 101(78.9) 0.081 0.96
AT 21 (19.1)   24 (18.8)
TT   2 (1.8)     3 (2.3)
rs3918188
CC 42 (38.2)   53 (41.4) 1.14 0.5729
CA 53 (48.2)   63 (49.2)
AA 15 (13.6)   12 (9.4)
rs1808593
TT 67 (60.9)   59 (46.1) 9.625 0.0081
TG 36 (32.7)   66 (51.6)
GG   7 (6.4)     3 (2.3)
TaBLE 3. association analysis of NOS3 rs1808783-rs1800779 
haplotypes with hypoxic-ischemic encephalopathy (hiE)
haplotype
hiE group 
frequencies
control group 
frequencies χ2 P
TA 0.586 0.594 0.027   0.08705
AG 0.359 0.398 0.777   0.3781
TG 0.021 0.046 0.000 <0.001MOLECULAR MEDICINE 400 Croat Med J. 2011; 52: 396-402
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is rare it is unlikely to have a major effect for disease devel-
opment in the population. One possible explanation of the 
biological mechanism through which it (or a causal variant 
that it is tagging) may exert its function is that it influences 
mRNA levels of NOS3 gene. The polymorphisms rs1800783 
and rs1800779 are located in the upstream and promoter 
region of the gene, which may influence mRNA transcrip-
tion and reduce gene expression and may further lead to 
impaired production or reduced bioavailability of nitric ox-
ide, causing susceptibility to severe clinical conditions in 
perinatal period (11,26). In fact, beneficial effects of inhaled 
nitric oxide in perinatology have been observed, especially 
in children with respiratory distress syndrome and bron-
chopulmonary dysplasia (27-29). Also, the treated infants 
had reduced incidence of brain injury and better neurode-
velopmental outcome than the control group at the age 
of 2 years (30-32).
So far, two studies have shown a correlation of NOS3 -922A 
(rs1800779)  polymorphism  with  cerebral  palsy  in  pre-
term infants (16,17). The first study observed NOS3 A-922G 
heterozygous AG and homozygous GG genotypes more 
frequently in the affected children. They also showed an 
association  of  functional  missense  NOS3  polymorphism 
rs1799983 (–894 G/T or Glu298Asp) with cerebral palsy, 
however we did not replicate this finding in our study (16). 
The second study revealed the association between NOS3 
promoter -922A (rs1800779) polymorphism and preterm 
birth among Caucasian children with cerebral palsy, but 
found no correlation for the second analyzed polymor-
phism, rs1799983 (-894 G/T) (Glu298Asp) of the same gene 
(17,33). In the present study, heterozygous TG genotype 
of rs1808593 SNP was found less frequently, whereas ho-
mozygous GG genotype was found more frequently in the 
group of HIE patients than in controls. However, genotypes 
for this SNP slightly deviated from HWE in controls, which 
may be the reason for the observed association. Therefore, 
the observed genotypic association can be an incidental 
finding. Two studies have associated NOS3 gene with hy-
poxic-ischemic brain damage, demonstrating the associa-
tion of T-786 C and Glu298Asp polymorphisms (20,21).
Limitations of this study are a small sample size and po-
tential population stratification due to possible relatedness 
among cases or controls in small populations (34). In light 
of this, future studies are needed to cover a larger part of 
Croatian population and provide the basis for further re-
search in understanding of the influence of this gene in 
HIE development. They should also include other risk 
factors and clinical parameters.
In conclusion, despite the limited number of HIE patients, 
which reduced the statistical power of this study, we ob-
served  genotype  and  haplotype  associations  of  NOS3 
polymorphisms with HIE, obtaining evidence of the impor-
tant role of this gene in susceptibility to hypoxic-ischemic 
perinatal damage. A complete comprehension of NOS3 
genetic contribution to HIE development is vital for un-
derstanding the disease etiology and future treatment of 
the disease. New diagnostic, prevention, and therapeutic 
approaches might derive from this knowledge; for exam-
ple, it might be useful to select children with high specific 
genetic risk for HIE development because low dose nitric 
oxide inhalation therapy may be a beneficial treatment. To-
day, such treatment is applied only in respiratory disorders 
(27,28) but it can also be used in the prevention hypoxic-
ischemic brain damage.
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